| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 08/02/2011 | CA2650546C Use of selected lactic acid bacteria for reducing infantile colic |
| 08/02/2011 | CA2518885C Pharmaceutical composition for intracellular acidification with cis-urocanic |
| 08/02/2011 | CA2488503C Dispersions of a solid in an aqueous liquid including a polyalkyleneglycol ester or amid of a fatty acid dimer and/or trimer |
| 08/02/2011 | CA2486678C Non-viral gene delivery system |
| 08/02/2011 | CA2475395C Anti-human tenascin monoclonal antibody |
| 08/02/2011 | CA2459493C New pharmaceutical compositions for inhalation |
| 08/02/2011 | CA2449298C A coated nicotine-containing chewing gum, manufacture and use thereof |
| 08/02/2011 | CA2436623C Branched polyalkylene glycols |
| 08/02/2011 | CA2423999C Compositions and medical devices utilizing bioabsorbable liquid polymers |
| 08/02/2011 | CA2419420C Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
| 08/02/2011 | CA2410990C Systems and methods for topical treatment with nitric oxide |
| 08/02/2011 | CA2368824C Rapid dehydration of proteins |
| 08/02/2011 | CA2366723C Fatty acid-anticancer conjugates and uses thereof |
| 08/02/2011 | CA2364451C Agent for treatment of arthritic disease |
| 08/02/2011 | CA2323757C Antibody variants and fragments thereof |
| 08/02/2011 | CA2323207C Food products having enhanced cocoa polyphenol content and processes for producing same |
| 08/02/2011 | CA2219275C Therapeutic agent and treatment for canine intractable dermatitis |
| 07/28/2011 | WO2011091411A2 Polyesters, methods of making polyesters and uses therefor |
| 07/28/2011 | WO2011091376A2 Immunogenic influenza composition |
| 07/28/2011 | WO2011091307A1 Affinity hydrogels for controlled protein release |
| 07/28/2011 | WO2011091098A2 Tooth whitening accelerator formulation and method of using the same |
| 07/28/2011 | WO2011091050A1 Oligomer-tricyclic conjugates |
| 07/28/2011 | WO2011090940A1 Cyclodextrin-based polymers for therapeutic delivery |
| 07/28/2011 | WO2011090725A2 Gastroretentive solid oral dosage forms with swellable hydrophilic polymer |
| 07/28/2011 | WO2011090724A2 Gastroretentive solid oral dosage forms with lipid-based low-density excipient |
| 07/28/2011 | WO2011090694A1 Orally administrable film dosage forms containing ondansetron |
| 07/28/2011 | WO2011090349A2 Nanocarrier having enhanced skin permeability, cellular uptake and tumour delivery properties |
| 07/28/2011 | WO2011090305A2 Liquid formulations for long-acting g-csf conjugate |
| 07/28/2011 | WO2011090088A1 Solution preparation containing stabilized antibody |
| 07/28/2011 | WO2011089255A1 Growth hormones with prolonged in-vivo efficacy |
| 07/28/2011 | WO2011089250A2 Stable growth hormone compounds |
| 07/28/2011 | WO2011089216A1 Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
| 07/28/2011 | WO2011089215A1 Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
| 07/28/2011 | WO2011089214A1 Carrier-linked carbamate prodrug linkers |
| 07/28/2011 | WO2011089170A2 Process for preparing fgf-21 with low degree of o-glycosylation |
| 07/28/2011 | WO2011089168A2 Special composition for the use thereof as a drug |
| 07/28/2011 | WO2011089062A2 Pharmaceutical formulation for proteins |
| 07/28/2011 | WO2011089004A1 Cancer stem cell markers and uses thereof |
| 07/28/2011 | WO2011088751A1 A human factor ix slow release dosage form |
| 07/28/2011 | WO2011088688A1 Polymer micelle medicine carrier comprising amino acid as stabilizer |
| 07/28/2011 | WO2011088550A1 Pharmaceutical formulations of loratadine for encapsulation and combinations thereof |
| 07/28/2011 | WO2011088532A1 Pharmaceutical compositions for the treatment of bacterial infections |
| 07/28/2011 | WO2011088503A1 Anaesthetic formulation |
| 07/28/2011 | WO2011059326A3 Hydrogels based on polymers of dextran tyramine and tyramine conjugates of natural polymers |
| 07/28/2011 | WO2011031617A3 Seamless alginate capsules |
| 07/28/2011 | WO2011031462A3 Compositions for delivery of insoluble agents |
| 07/28/2011 | WO2011009991A3 Dendritic pic micelles with bioactive proteins |
| 07/28/2011 | WO2008137733A3 Micellar structures, methods of making micellar structures, methods of imaging, and methods of delivering agents |
| 07/28/2011 | US20110184153 Modified gherlin peptides |
| 07/28/2011 | US20110184073 Assay |
| 07/28/2011 | US20110184062 Compositions and methods for dry eye syndrome |
| 07/28/2011 | US20110184039 Pharmaceutical formulation |
| 07/28/2011 | US20110184037 Methods for treating an intervertebral disc using local analgesics |
| 07/28/2011 | US20110183934 Methods and compositions to improve germ cell and embryo survival and function |
| 07/28/2011 | US20110183913 Novel lipid dipeptide and gel |
| 07/28/2011 | US20110183376 Novel anti-igf-ir antibodies and uses thereof |
| 07/28/2011 | US20110182996 Surface modified nanoparticles, methods of their preparation, and uses thereof for gene and drug delivery |
| 07/28/2011 | US20110182990 Nanocomposite hydrogel and method for preparing it, for industrial and medical applications |
| 07/28/2011 | US20110182988 Gastroretentive pharmaceutical dosage form |
| 07/28/2011 | US20110182987 Pharmaceutical dosage form for the site-specific delivery of more than one active pharmaceutical ingredient |
| 07/28/2011 | US20110182986 Controlled release composition |
| 07/28/2011 | US20110182985 Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| 07/28/2011 | US20110182969 Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
| 07/28/2011 | US20110182967 Implants for administering substances and methods of producing implants |
| 07/28/2011 | US20110182947 Hydrogel-driven drug dosage form |
| 07/28/2011 | US20110182896 CLOTTING FACTOR-Fc CHIMERIC PROTEINS TO TREAT HEMOPHILIA |
| 07/28/2011 | US20110182893 Prevention and treatment of amyloidogenic diseases |
| 07/28/2011 | US20110182864 Compositions containing inclusion complexes |
| 07/28/2011 | US20110182857 Delivery of Drugs to Mucosal Surfaces |
| 07/28/2011 | US20110182855 Conjugated biological molecules and their preparation |
| 07/28/2011 | US20110182813 Amphiphilic copolymers and compositions containing such polymers |
| 07/28/2011 | US20110182806 Systems and methods for particle radiation enhanced delivery of therapy |
| 07/28/2011 | CA2792993A1 Special composition for the use thereof as a drug |
| 07/28/2011 | CA2787974A1 Immunogenic influenza composition |
| 07/28/2011 | CA2787895A1 Stable growth hormone compounds |
| 07/28/2011 | CA2787890A1 Growth hormones with prolonged in-vivo efficacy |
| 07/28/2011 | CA2787648A1 Liquid formulations for long-acting g-csf conjugate |
| 07/28/2011 | CA2787514A1 Intracameral sustained release therapeutic agent implants |
| 07/28/2011 | CA2787156A1 Synthetic nanostructures including nucleic acids and/or other entities |
| 07/28/2011 | CA2786981A1 Stabilized antibody-containing liquid formulations |
| 07/28/2011 | CA2786952A1 Pharmaceutical formulation for proteins |
| 07/28/2011 | CA2786880A1 Antimicrobial agents and methods of use |
| 07/28/2011 | CA2786762A1 Anaesthetic formulation |
| 07/28/2011 | CA2786212A1 Cancer stem cell markers and uses thereof |
| 07/28/2011 | CA2785860A1 Gastroretentive solid oral dosage forms with swellable hydrophilic polymer |
| 07/28/2011 | CA2784587A1 Orally administrable film dosage forms containing ondansetron |
| 07/28/2011 | CA2783001A1 Sustained-release nucleic acid matrix compositions |
| 07/28/2011 | CA2729484A1 Film-form preparation |
| 07/27/2011 | EP2348119A2 Multicistronic lentiviral vector |
| 07/27/2011 | EP2348114A1 Bone delivery conjugates and method of using same to target proteins to bone |
| 07/27/2011 | EP2348032A2 6.Alpha.,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothiotic acid s-fluoromethyl ester as an anti-inflammatory agent |
| 07/27/2011 | EP2348024A2 Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| 07/27/2011 | EP2347771A1 Peptide-based compounds for targeted imaging |
| 07/27/2011 | EP2347770A2 Process for producing an injectable pharmaceutical preparation |
| 07/27/2011 | EP2347769A1 Cancer stem cell markers and uses thereof |
| 07/27/2011 | EP2347764A2 Method of obtaining cochlear structures, vaccine compositions, adjuvants and intermediates thereof |
| 07/27/2011 | EP2347756A2 Controlled agglomeration |
| 07/27/2011 | EP2346906A1 Conjugates of glp-1 agonists and uses thereof |
| 07/27/2011 | EP2346896A1 Etoposide and doxorubicin conjugates for drug delivery |
| 07/27/2011 | EP2346532A2 Targeting construct comprising anti-polymer antibody and liposomes or microvesicles binding to the same |